These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32537176)

  • 61. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
    Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
    Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
    J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Radioresistance in Glioblastoma and the Development of Radiosensitizers.
    Ali MY; Oliva CR; Noman ASM; Allen BG; Goswami PC; Zakharia Y; Monga V; Spitz DR; Buatti JM; Griguer CE
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899427
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore.
    Paradkar S; Herrington J; Hendricson A; Hewawasam P; Plummer M; Hoyer D; Sundaram RK; Surovtseva YV; Bindra RS
    Oncotarget; 2021 Apr; 12(9):891-906. PubMed ID: 33953843
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Six degrees of separation: the oxygen effect in the development of radiosensitizers.
    Oronsky BT; Knox SJ; Scicinski J
    Transl Oncol; 2011 Aug; 4(4):189-98. PubMed ID: 21804913
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A new class of radiosensitizers for glioblastoma.
    Abounader R; Schiff D
    Oncotarget; 2021 Jun; 12(13):1199-1200. PubMed ID: 34194618
    [No Abstract]   [Full Text] [Related]  

  • 67. Regulation of cancer stem cells and immunotherapy of glioblastoma (Review).
    Kosianova А; Pak O; Bryukhovetskiy I
    Biomed Rep; 2024 Feb; 20(2):24. PubMed ID: 38170016
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
    Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Application of nano-radiosensitizers in combination cancer therapy.
    Varzandeh M; Sabouri L; Mansouri V; Gharibshahian M; Beheshtizadeh N; Hamblin MR; Rezaei N
    Bioeng Transl Med; 2023 May; 8(3):e10498. PubMed ID: 37206240
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
    Waqar M; Trifiletti DM; McBain C; O'Connor J; Coope DJ; Akkari L; Quinones-Hinojosa A; Borst GR
    Curr Oncol Rep; 2022 Mar; 24(3):311-324. PubMed ID: 35119629
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?
    Wee CW
    Brain Tumor Res Treat; 2022 Jan; 10(1):12-21. PubMed ID: 35118843
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.
    Kaynak A; Davis HW; Vallabhapurapu SD; Pak KY; Gray BD; Qi X
    Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832975
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.
    Yamamoto M; Sanomachi T; Suzuki S; Togashi K; Sugai A; Seino S; Sato A; Okada M; Kitanaka C
    Neurooncol Adv; 2021; 3(1):vdab148. PubMed ID: 34765973
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Radiosensitization of calreticulin-overexpressing human glioma cell line by the polyphenolic acetate 7, 8-diacetoxy-4-methylcoumarin.
    Verma A; Arora A; Bhatt AN; Arya MB; Prasad AK; Parmar VS; Dwarakanath BS
    Cancer Rep (Hoboken); 2022 Dec; 5(12):e1326. PubMed ID: 34472223
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
    Choi J; Kim G; Cho SB; Im HJ
    J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.
    Mathen P; Rowe L; Mackey M; Smart D; Tofilon P; Camphausen K
    Neurooncol Pract; 2020 Jun; 7(3):268-276. PubMed ID: 32537176
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
    Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
    Degorre C; Tofilon P; Camphausen K; Mathen P
    Radiat Oncol; 2021 Sep; 16(1):191. PubMed ID: 34583727
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.